Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Category Primary study
JournalTherapeutic Advances in Medical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: 056126a8257ee40b9de6e0c1741ea4ab4dde8a96
First added on: Feb 16, 2025